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http://dx.doi.org/10Granulocyte colony-stimulating factor (G-CSF) is used routinely in the clinical setting to
mobilize hematopoietic stem progenitor cells (HSPCs) into the patient’s blood for collection
and subsequent transplantation. However, a significant proportion of patients who have pre-
viously received chemotherapy or radiotherapy and require autologous HSPC transplantation
cannot mobilize the minimal threshold of mobilized HSPCs to achieve rapid and successful
hematopoietic reconstitution. Although several alternatives to the G-CSF regime have been
tested, few are used in the clinical setting. We have shown previously in mice that administra-
tion of prolyl 4-hydroxylase domain enzyme (PHD) inhibitors, which stabilize hypoxia-
inducible factor (HIF)-1a, synergize with G-CSF in vivo to enhance mouse HSPC mobilization
into blood, leading to enhanced engraftment via an HSPC-intrinsic mechanism. To evaluate
whether PHD inhibitors could be used to enhance mobilization of human HSPCs, we human-
ized nonobese, diabetic severe combined immune-deficient Il2rgL/L mice by transplanting
them with human umbilical cord blood CD34+ HSPCs and then treating them with G-CSF
with and without co-administration of the PHD inhibitor FG-4497. We observed that combi-
nation treatment with G-CSF and FG-4497 resulted in significant mobilization of human
lineage-negative (LinL) CD34+ HSPCs and more primitive human LinLCD34+CD38L HSPCs
into blood and spleen, whereas mice treated with G-CSF alone did not mobilize human HSPCs
significantly. These results suggest that the PHD inhibitor FG-4497 also increases human
HSPC mobilization in a xenograft mouse model, suggesting the possibility of testing PHD in-
hibitors to boost HSPC mobilization in response to G-CSF in humans. Copyright  2017
ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.Granulocyte-stimulating factor (G-CSF) is used in the clin-
ical setting to mobilize CD34þ hematopoietic stem and
progenitor cells (HSPCs) into the blood for subsequent trans-
plantation [1]. Autologous HSPC transplantations, which
represent half of all HSC transplantations, increase survival
rates of relapsed non-Hodgkin’s lymphoma patients and
multiple myeloma patients [2,3]. In the autologous trans-
plantation setting, 20–60% of patients previously treatedtributed equally to this work.
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.1016/j.exphem.2017.05.004with repeated cycles of high-dose chemotherapy or radio-
therapy fail to mobilize the minimum threshold of 2  106
CD34þ cells/kg required for rapid hematopoietic reconstitu-
tion [4], precluding potentially curative autologous HSPC
transplantation. The synthetic CXCR4 chemokine receptor
antagonist AMD3100/Plerixafor synergizes with G-CSF to
promote HSPC mobilization and salvages mobilization in
about 70% of poor mobilizers [5,6]. Because Plerixafor is
the only drug approved by the U.S. Food and Drug Admin-
istration that boosts HSPC mobilization, there remains
considerable scope to identify alternative strategies to further
improve HSPC mobilization in poor mobilizers [4].
Recently, we have demonstrated in mice that HSPC-
autonomous stabilization of oxygen-labile transcription
factor hypoxia-inducible factor (HIF)-1 is necessary for
mobilization in response to G-CSF or Plerixafor [7].
In mice, pharmacological stabilization of HIF-1 with HIFmatology. Published by Elsevier Inc.
2 B. Nowlan et al./ Experimental Hematology 2017;-:-–-prolyl 4-hydroxylase domain enzyme inhibitors, such as
FG-4497, synergized with both G-CSF and Plerixafor to
boost HSC mobilization into the blood [7]. To confirm
the role of HIF-1a and its pharmacological stabilization
in human HSPC mobilization, we tested the combination
of G-CSF plus FG-4497 in human CD34þ HSPC xenografts
in immune-deficient mice.Methods
Xenograft
Purified human cord blood CD34þ cells were purchased from
STEMCELL Technologies (Vancouver, Canada). Cell transplanta-
tions were completed as previously described [8]. In brief, female
non-obese, diabetic severe combined immune-deficient Il2rg/
(NSG) mice at 6–8 weeks of age were sublethally irradiated
(2.5 Gy) 24 hours before transplantation. Mice were anesthetized
with isoflurane inhalation, and 50  103 freshly thawed CD34þ
cells were injected intravenously retro-orbitally. At 6 and 8 weeks
after transplantation, blood was collected from mice by subman-
dibular bleed for flow cytometry analysis to measure human
CD45þ leukocyte engraftment. Based on the 8-week bleed, mice
were distributed into groups with similar human leukocyte chime-
rism (Supplementary Figure E1, online only, available at www.
exphem.org).
Mobilization
Six different treatment groups (Supplementary Figure E2, online
only, available at www.exphem.org) were used: saline alone for
4 days (S), FG-4497 alone for 3 days (F3), G-CSF alone for 2
(G2) or 4 days (G4), and 3 days of FG-4497 co-administrated
with G-CSF for 2 (G2F3) or G-CSF for 4 days (G4F3).
Mice were administrated with recombinant human G-CSF (Fil-
grastim, Amgen) twice daily subcutaneously at 125 mg/kg or with
saline for 2 or 4 days before harvest. FG-4497 20 mg/kg (Fibro-
gen, San Francisco, CA), or vehicle was injected intraperitoneally
daily for the last 3 days before tissue harvest as previously
described [7].
Tissue harvest and flow cytometry
For details of tissue harvest and flow cytometry, please see the
Supplementary Methods and Supplementary Table E1 (online
only, available at www.exphem.org).
Statistics
To account for the different levels of human hematopoietic engraft-
ment between each recipient mouse, we normalized the numbers of
mobilized human HSPCs (huCD45þLin– CD34þ or huCD45þLin
CD34þCD38) to the percentage of human chimerism in blood at
8 weeks after transplantation (before mobilization). This normali-
zation was performed using the following equation:
HSPC per mL blood or per spleen
%huCD45þ leukocytes in blood at week 8
All statistical analyses were performed using Prism software
(GraphPad, La Jolla, CA). Sample groups were tested for outlying
data using Prism. Data were analyzed using one-way analysis of
variance (ANOVA) with Tukey’s correction for multiple
comparisons.Results and discussion
To test whether a combination of the PHD inhibitor FG-
4497 with G-CSF could mobilize human HSPCs, we trans-
planted 42 NSG mice with 50,000 thawed human cord
blood CD34þ cells. Eight weeks after transplantation, we
measured human leukocyte engraftment, which ranged
from 20% to 60% total blood leukocytes (Supplementary
Figure E1). Considering this wide range of human chime-
rism, we distributed the 42 mice across six experimental
groups to have similar averages and standard deviations
in human leukocyte chimerism. Two weeks later, mice
were injected with saline, FG-4497 alone, G-CSF alone,
or the combination of G-CSF plus FG-4497
(Supplementary Figure E2).
At the endpoint of the experiment, blood and spleen con-
tent in human CD45þLinCD34þ HSPCs and more primi-
tive CD45þLinCD34þCD38 HSPCs were measured by
flow cytometry. Considering the highly variable levels of
human leukocyte chimerism between mice from each
experimental group (range: 9.3% to 61.0%;
Supplementary Table E2, online only, available at www.
exphem.org), the number of human HSPCs mobilized in
each tissue was normalized relative to the percentage of hu-
man chimerism before treatment by dividing the number of
mobilized HSPCs by the proportion of human CD45þ leu-
kocytes in the blood of each individual mouse before treat-
ment. (At an equivalent level of HSPC mobilization, one
would expect that a mouse with 60% human chimerism
would mobilize sixfold more human HSPCs per milliliter
of blood and spleen than a mouse with 10% human
chimerism.)
After this normalization relative to human engraftment,
G-CSF alone did not increase human CD45þLinCD34þ
HSPC cell mobilization in the blood of NSG mice at either
time point compared with the saline-treated group
(p 5 0.44 G2 vs. S; p 5 0.47 G4 vs. S by ANOVA;
Fig. 1A–D). However, the combination of FG-4497 plus
G-CSF for 2 days (G2F3) or 4 days (G4F3) significantly
mobilized human CD45þLin–CD34þ HSPCs (p 5 0.0204
G2F3 vs. saline; p 5 0.0059 G4F3 vs. saline by ANOVA;
Fig. 1A, 1F–H). Therefore, the addition of FG-4437 to G-
CSF significantly mobilized human CD45þLinCD34þ
HSPCs into the blood of NSG mice, whereas G-CSF alone
did not. More primitive CD45þLinCD34þCD38 HSPCs
were significantly mobilized at day 4 of G-CSF treatment,
irrespective of FG-4497 treatment, which did not further in-
crease their mobilization into the blood (Fig. 1E).
Because the spleen is a sieve in which mobilized HSPCs
accumulate during mobilizing treatments, we measured the
number of human HSPCs in this organ. G-CSF alone or in
combination with FG-4497 did not cause significant accu-
mulation of HSPCs into the spleen after 2 days of G-CSF
treatment (Fig. 2A and 2E). However, at day 4 of G-CSF
treatment, the combination with FG-4497 caused a signifi-
cant increase in the number of CD45þ Lin CD34þ HSPCs
Figure 1. FG-4497 increases mobilization of human HSPCs into the blood in response to human G-CSF in transplanted NSG mice. (A) Human
CD45þLinCD34þ cells mobilized into peripheral blood normalized to human CD45þ leukocyte engraftment at 8 weeks after transplantation. S 5 saline
for 4 days; F3 5 G-4497 for 3 days; G2 5 G-CSF for 2 days; G4 5 G-CSF for 4 days. Each dot represents an individual mouse from each group; average
and standard deviations are shown for each group. p values were calculated by ANOVAwith Tukey’s correction for multiple comparisons. Shown are represen-
tative flow cytometry dot-plots for peripheral blood from mice treated with saline (B) or G-CSF alone for 2 days (C) or 4 days (D). Dot-plots show expression of
human CD34 versus CD38 on blood cells within the live gate and human CD45þLin gate. (E) FG-4497 increases the mobilization of more primitive human
CD45þLinCD34þCD38 HSPCs into the blood in response to human G-CSF in transplanted NSG mice. Representative flow cytometry dot-plots are shown for
spleens from mice treated with FG-4497 alone (F), and within the box, FG-4497 plus G-CSF for 2 days (G) or 4 days (H).
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Figure 2. FG-4497 increases mobilization of human HSPCs into the spleen in response to human G-CSF in transplanted NSG mice. (A) Human
CD45þLinCD34þ cells mobilized to the spleen normalized to human CD45þ leukocyte engraftment at 8 weeks after transplantation. S 5 saline for
4 days; F35FG-4497 for 3 days; G2 5 G-CSF for 2 days; G4 5 G-CSF for 4 days. Each dot represents an individual mouse from each group; average
and standard deviations are shown for each group. p values were calculated by ANOVA with Tukey’s correction for multiple comparisons. Representative
flow cytometry dot-plots are shown for peripheral blood from mice treated with saline (B) or G-CSF alone for 2 days (C) or 4 days (D). (E) FG-4497 in-
creases mobilization of more primitive human LinCD34þCD38 HSPCs to the spleen in response to human G-CSF in transplanted NSG mice. Represen-
tative flow cytometry dot-plots are shown for spleens from mice treated with FG-4497 alone (F), and within the box, FG-4497 plus G-CSF for 2 days (G) or
4 days (H). Dot-plots show human CD34 versus CD38 within the live gate and human CD45þLin gate.
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mice (p ! 104 by ANOVA), whereas mice treated with
G-CSF alone did not (p 5 0.26 by ANOVA; Fig. 2A–D).
Likewise, CD45þ LinCD34þCD38 HSPCs were also
significantly increased in the spleen at day 4 of G-CSF
plus FG-4497 compared with the saline-treated group
(p ! 104 by ANOVA), whereas they were not increased
in mice treated with G-CSF alone for 4 days (p 5 0.10
by ANOVA; Fig. 2E–H). There was significantly higher
accumulation of CD45þLinCD34þ HSPCs in the spleen
of animals treated with G-CSF for 4 days plus FG-4497
than in those treated with G-CSF alone (p 5 0.0128, AN-
OVA), whereas there was a trend of higher accumulation
of CD45þLinCD34þ HSPCs in the spleen after G4F3
treatment versus G4 (p 5 0.079, ANOVA).
The poor efficacy of human G-CSF to mobilize human
HSPCs in NSG mice in our experiments is consistent
with previous publications [9,10]. Poor human HSPC mobi-
lization in humanized NSG or NOD/SCID mice has been
linked to lack of immunoglobulins that promote the activa-
tion of complement proteins C3 and C5 in response to G-
CSF [10–12] and the formation of the membrane attack
complex that lyses blood erythrocytes, releasing the chemo-
attractant shingossine-1-phosphate into the blood [13,14].
In addition, irradiation of mice before transplantation could
further account for poor HSPC mobilization [4,15]. Indeed,
total body irradiation and cytotoxic drugs damage the BM
stroma in humans [4,16,17] and mice [18,19] in a similar
manner and decrease subsequent HSPC mobilization.
Despite these limitations of humanized NSG and NOD/
SCID mice [9,10] as models of HSPC mobilization, we
observed significant human HSPC mobilization in response
to G-CSF plus FG-4497 combination in the blood as early
as day 2 of G-CSF and in the spleen at day 4 of G-CSF,
whereas NSG mice did not mobilize efficiently in response
to G-CSF alone. These results are consistent with the mobi-
lization profile of mouse HSPCs in immune-competent
mice, in which HSPC mobilization plateaus in the periph-
eral blood at day 4 of G-CSF administration and starts accu-
mulating in the spleen from day 4 onward [20,21].
Therefore, our results suggest that additional pharmacolog-
ical stabilization of FG-4497 rescues the mobilization
defect in response to G-CSF in NSG mice.
We have demonstrated previously that the effect of FG-
4497 on mouse HSPC mobilization in response to G-CSF is
mostly HSPC autonomous, because conditional deletion of
the Hif1a gene in mouse HSPC abolishes the effect of FG-
4497 on HSPC mobilization [7]. Therefore, by inference,
the enhancing effect of FG-4497 on human HSPC mobili-
zation in response to G-CSF in humanized NSG mice
may be caused by the cell-autonomous effects of HIF-1 sta-
bilization, which can partly rescue the HSPC extrinsic
mechanism defect in NSG mice.
In conclusion, we have found that the PHD inhibitor FG-
4497 rescues human HSPC mobilization in G-CSF–treatedNSG mice transplanted with human umbilical cord CD34þ
cells. The related PHD inhibitor FG-4592 is well tolerated
in humans and is already in clinical trials for correcting the
anemia associated with chronic kidney disease [22], opening
the way for testing the use of PHD inhibitors in combination
with G-CSF to enhance HSPC mobilization in humans.Acknowledgments
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Supplementary Figure E1. Engraftment of human CD45þ leukocytes in
blood of NSG mice transplanted with human cord blood CD34þ cells.
Human CD45þ leukocyte chimerism was measured by flow cytometry
8 weeks post-transplantation. Following measurement in each individual
mouse, mice were allocated in the indicated experimental groups in order
to have similar mean and standard deviation between all the groups. Dots
represent values for each mouse. Error bars are average 6 standard devi-
ation for each allocated experimental group.
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Supplementary Figure E2. Injection schedule of CD34þ transplanted NSG mice. Recombinant human G-CSF was injected subcutaneously twice daily
at 125 mg kg1 for 2 to 4 days before harvest. FG-4497 was injected intraperitoneally daily at 20 mg kg1 3 days before harvest as previously described.
For control groups, equivalent volumes of saline and dextrose vehicle were used in place of G-CSF and FG-4497 respectively.
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Supplementary Figure E3. Gating strategy for analysis of human CD34þ HSPC mobilization in NSG mice transplanted with human cord blood
CD34þ cells. Sample shown is blood from a FG4497þG-CSF day2 mouse treated mouse.
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Supplementary Table E1. Antibodies and dilutions used
Target Antibody Clone Source Dilution
bleed mouse CD16/32 (FcBlock) 2.4G2 BD Bioscience 1/200
mouse CD45-APC 30-F11 Biolegend 1/200
human CD45-VioBright FITC 5B1 Miltenyi Bioscience 1/60
human CD33-BV421 WM53 Biolegend 1/20
human CD19-PECy7 HIB19 Biolegend 1/50
human CD3-APCCy7 HIT3a Biolegend 1/50
human CD15-PE H198 Miltenyi Bioscience 1/50
harvest mouse CD16/32 (FcBlock) 2.4G2 BD Bioscience 1/200
mouse CD45-BV605 30-F11 Biolegend 1/200
human CD45-VioBright FITC 5B1 Miltenyi Bioscience 1/60
human CD33-BV421 WM53 Biolegend 1/20
human CD19-PECy7 HIB19 Biolegend 1/50
human CD3-APCCy7 HIT3a Biolegend 1/50
human CD34-APC AC136 Miltenyi Bioscience 1/30
human CD38-PE 1B6 Miltenyi Bioscience 1/40
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Supplementary Table E2. Levels of Engraftment per mouse at week 8 post-transplant and human CD34þ cells mobilized into blood and spleen
neelpSdoolBxtkw8
43DCuh+54DCuh%spuorG +/mL x103 Average St Dev huCD34+/spleen x106 Average St Dev
Saline d4
.0425.1721.2%1.83 883.0657.0085.1344
873.0598.0%9.42
028.0085.1%4.53
554.0131.1%9.52
067.0222.1%0.33
169.0721.2%0.55
106.0335.1%9.83
294.0085.1%9.61
FG-4497 d3
.1359.1472.4%8.04 725.0582.1568.0831
690.1712.2%5.72
156.1245.1%5.82
766.0569.0%9.93
457.1380.1%9.54
799.1633.1%2.63
985.1309.2%4.74
856.0403.1%2.72
G-CSF d2
.2303.4020.6%2.62 915.0200.1102.1345
684.0866.2%8.64
627.0592.4%0.72
802.1203.9%6.22
260.2875.6%2.63
234.1660.3%3.53
447.0993.1%9.81
985.0443.3%7.63
475.0650.2%5.35
G-CSF d2+ FG-4497 d3
.4313.7539.2%3.9 565.0963.1243.0156
029.0252.6%9.43
145.1907.31%7.32
530.1769.5%5.03
271.2857.21%8.83
766.1957.3%3.63
927.1598.6%0.35
570.1053.3%7.91
708.0412.3%1.05
629.1116.5%0.93
148.1899.51%0.16
G-CSF d4
.3642.4417.1%0.92 720.1615.1404.0240
768.0305.4%9.53
408.2045.01%2.03
993.1363.6%0.52
239.1235.4%9.91
736.0667.1%6.65
371.3185.2%8.83
619.0869.1%1.82
G-CSF d4+ FG-4497 d3
.3001.8605.11%8.12 742.1800.3442.3543
433.2711.4%0.12
577.4958.7%2.65
201.2843.9%4.53
030.5412.31%2.82
517.1652.7%0.63
994.2231.8%0.24
863.2173.3%9.82
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Tissue Harvest
Mice were anesthetized with isoflurane and blood collected with heparin-EDTA by cardiac puncture, 
and then euthanized to collect femurs and spleens. Bone marrow (BM) was flushed from the femur 
using a 23 gauge needle with 1mL PBS with 2% fetal bovine serum. Spleens were disassociated into 
single cell suspension using the GentleMACS Dissociator (Miltenyi, Bergisch Gladbach, Germany) in 
a C type gentleMACS tube (Miltenyi). Red blood cells were lysed in blood samples as previously 
described [9]. Cell counts were completed on a Coulter AcT Diff Analyzer (Beckman Coulter), 
reported as cells per fraction for analysis.
Flow Cytometry
Human chimerism levels: Red Blood cells were lysed by adding 4ml of red cell lysis buffer: 150mM 
NH4Cl, 10mM Tris-HCl, 1mM EDTA pH=7.4 and a 6 minute incubation at room temperature with 
gently rocking before centrifugation at 4*C to eliminate cell debris. Lysed blood cells were washed 
twice with PBS containing 2% fetal bovine serum, then incubated with purified rat anti-mouse (mu) 
CD16/CD32 antibody (FcBlock) (BD Bioscience) and stained with fluorescence-conjugated 
antibodies as outlined in supplementary table 1. 7-amino-actinomycin D (7-AAD) (Invitrogen) was 
used for live dead discrimination. Human leukocytes were numerated as muCD45-huCD45+ cells and 
mouse leukocytes as muCD45+huCD45- cells. For each individual mouse, human CD45+ chimerism 
percentage was calculated as the ratio of huCD45+ leukocytes over total number of human and mouse 
CD45+ leukocytes in the blood at 8 weeks post-transplantation. 
For measurements of human cell mobilization, 5x106 cells from blood, BM and spleen from each 
mouse were blocked with muFcBlock and then stained with fluorescence-conjugated antibody 
cocktail antibodies as outlined in supplementary table 1. Cells were analyzed on a CyAn flow 
cytometer (Beckman Coulter) and post-acquisition compensated and analyzed with FlowJo software 
(Ashland, OR). Human HPSC were defined as muCD45-, huCD45+, lineage (CD33, CD19 and CD3) 
negative (Lin-), and huCD34+. Primitive HSPC were defined as muCD45-huCD45+Lin-CD34+CD38-
(Supplementary figure 3). 
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